Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30912922 | 1.00 | ACHE (0.58) | ACHECYP3A4HPGDLMNATP53 | |
| Nitric Acid SCHEMBL11333284 | 0.86 | ACHE (0.44) | ACHECYP3A4HPGDLMNATP53 | |
| Nitric Acid SCHEMBL11333283 | 0.86 | ACHE (0.44) | ACHECYP3A4HPGDLMNATP53 | |
| SCHEMBL3534896 | 0.83 | ACHE (0.54) | ACHECYP3A4HPGDLMNATP53 | |
| SCHEMBL12180296 | 0.83 | ACHE (0.54) | ACHECYP3A4HPGDLMNATP53 | |
| SCHEMBL1038127 | 0.83 | ACHE (0.58) | ACHECYP3A4HPGDLMNATP53 | |
| SCHEMBL6061341 | 0.81 | ACHE (0.47) | ACHEALDH1A1L3MBTL1HTTKDM4E | |
| SCHEMBL12073737 | 0.81 | ACHE (0.56) | ACHECYP3A4HPGDALDH1A1L3MBTL1 | |
| SCHEMBL13019887 | 0.81 | L3MBTL1 (0.45) | ACHECYP3A4HPGDTP53ALDH1A1 | |
| SCHEMBL28942882 | 0.81 | HTT (0.45) | ACHECYP3A4HPGDLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105789-A | Preparation and refining method of musk with sunflower seeds | 濮阳市元泰精细化工有限公司 | 2023-11-24 | — | — | CN | claimed |
| US-4288638-A | Process for the synthesis of 2,4-dinitro-6-t-butyl-3-methylanisole, referred to as musk ambrette | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1981-09-08 | — | — | US | claimed |
| US-4236029-A | Process for the synthesis of 2,4-dinitro-6-t-butyl-3-methylanisole, referred to as musk ambrette | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1980-11-25 | — | — | US | claimed |
| US-4233463-A | Process for the separation of 2,4-dinitro-6-t-butyl-3-methylanisole, referred to as musk ambrette, from the crude synthesis mixtures in which it is present | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1980-11-11 | — | — | US | claimed |
| CN-117105789-B | Preparation and refining method of musk with sunflower seeds | 濮阳市元泰精细化工有限公司 | 2025-12-09 | — | — | CN | disclosed |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-07-04 | — | — | US | disclosed |
| CN-117865809-A | Preparation method of musk with sunflower seeds | 山东兴文工业技术研究院有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117599458-A | Sunflower seed musk crystallization plate | 濮阳市元泰精细化工有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117504343-A | Rotary disc type crystallizer | 濮阳市元泰精细化工有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834689-B2 | Incorporation of unnatural nucleotides and methods thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| EP-0612723-A1 | Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-08-31 | — | — | EP | disclosed |
| US-4288638-A | Process for the synthesis of 2,4-dinitro-6-t-butyl-3-methylanisole, referred to as musk ambrette | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1981-09-08 | — | — | US | disclosed |
| US-4288638-A | Process for the synthesis of 2,4-dinitro-6-t-butyl-3-methylanisole, referred to as musk ambrette | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1981-09-08 | — | — | US | disclosed |
| US-4236029-A | Process for the synthesis of 2,4-dinitro-6-t-butyl-3-methylanisole, referred to as musk ambrette | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1980-11-25 | — | — | US | disclosed |
| US-4236029-A | Process for the synthesis of 2,4-dinitro-6-t-butyl-3-methylanisole, referred to as musk ambrette | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1980-11-25 | — | — | US | disclosed |
| US-4233463-A | Process for the separation of 2,4-dinitro-6-t-butyl-3-methylanisole, referred to as musk ambrette, from the crude synthesis mixtures in which it is present | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1980-11-11 | — | — | US | disclosed |
| US-4233463-A | Process for the separation of 2,4-dinitro-6-t-butyl-3-methylanisole, referred to as musk ambrette, from the crude synthesis mixtures in which it is present | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1980-11-11 | — | — | US | disclosed |
| US-4219570-A | Insect repellents and a method of repelling insects | AJINOMOTO COMPANY, INCORPORATED (JP) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | ACHE 27/4885CYP3A4 1038/4885HPGD 2135/4885 |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | SLC35B2, SLC29A2, PNP | ACHE 1829/4885CYP3A4 1893/4885HPGD 1589/4885 |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | SLC35B2, SLC29A2, PNP | ACHE 1829/4885CYP3A4 1893/4885HPGD 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.